Aditum Bio is dedicated to enhancing patient access to promising therapeutics that may not otherwise progress to clinical development. Co-founded by industry leaders Joe Jimenez and Mark Fishman, Aditum Bio identifies and in-licenses innovative drug candidates, focusing on the crucial translational phases of Phase I and Phase II clinical trials. Their mission is to generate vital data that supports complete clinical development and market introduction of these therapies, ensuring that patients in need receive lifesaving medications.